More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$131013339
EPS
-0.82
P/E ratio
--
Price to sales
1.42
Dividend yield
--
Beta
1.335349
Previous close
$2.17
Today's open
$2.13
Day's range
$2.02 - $2.18
52 week range
$1.32 - $5.08
show more
CEO
Eric Risser
Employees
293
Headquarters
Rockville, MD
Exchange
Nasdaq Global Select
Shares outstanding
63908946
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients First patient dosed with MGC030 in Phase 1 study Strengthened Board with addition of two new independent directors with expertise in oncology drug discovery and development Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028 ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.
GlobeNewsWire • Nov 12, 2026

MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to earnings of $0.27 per share a year ago.
Zacks Investment Research • Nov 12, 2026

MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference (New York, NY). MacroGenics' President and CEO, Eric Risser, will participate in a fireside chat on Wednesday, November 11, at 10:00 am ET.
GlobeNewsWire • Nov 5, 2026

MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D.
ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D.
GlobeNewsWire • Nov 3, 2026

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
GlobeNewsWire • Oct 26, 2026

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
GlobeNewsWire • Oct 23, 2026

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) directed against an undisclosed target, in patients with advanced solid tumors. “MGC030 demonstrated encouraging antitumor activity in multiple preclinical models, and we look forward to advancing this product candidate through the Phase 1 study.
GlobeNewsWire • Oct 15, 2026

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Zacks Investment Research • Oct 9, 2026

Stock Picks From Seeking Alpha's September 2026 New Analysts
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.
Seeking Alpha • Oct 7, 2026

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.
GlobeNewsWire • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MacroGenics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.